- Raw materials
- Levocarnitine propionate
Filters
Filter
Custom request?
Type
Production region
Qualifications
Country of origin
Levocarnitine propionate API Manufacturers & Suppliers
1 verified results
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency
|
Supplier trade data access
|
Buyer / supplier flow comparison
Commercial-scale Suppliers
Distributor
Produced in
China|
Employees: 50+
|
Audit Report:
Certifications:
GMP
|
CEP|
ISO9001|
CoAAll certificates
GMP
CEP
ISO9001
CoA
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Get full market intelligence report
€399,-
All Levocarnitine propionate data. Full access. Full negotiation power
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency
|
Supplier trade data access
|
Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Levocarnitine propionate | CAS No: 20064-19-1 | GMP-certified suppliers
A medication that supports metabolism modulation and mitochondrial function, primarily investigated for potential benefits in energy production disorders.
Generic name
Levocarnitine propionate
Molecule type
small molecule
CAS number
20064-19-1
DrugBank ID
DB15980
Approval status
Experimental drug
Product Snapshot
- Levocarnitine propionate is formulated as an injectable powder for solution intended for parenteral administration
- The compound is primarily used in metabolic and mitochondrial disorders requiring carnitine supplementation
- It is currently designated as experimental and has not received approval from key regulatory agencies such as FDA or EMA
Clinical Overview
Levocarnitine propionate (CAS number 20064-19-1) is an experimental pharmaceutical compound related to the class of carnitine derivatives. While specific clinical indications have not been fully established, compounds within this chemical category are generally investigated for their potential roles in metabolism modulation and mitochondrial function support.
Pharmacologically, levocarnitine propionate is presumed to act similarly to other carnitine esters by facilitating the transport of long-chain fatty acids across the mitochondrial membrane. This transport is critical for beta-oxidation and subsequent energy production within cells. However, detailed pharmacodynamic data and explicit mechanism of action for this specific propionate ester remain to be fully characterized in clinical or preclinical settings.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for levocarnitine propionate have not been reported in the available literature. Given its structural relationship to levocarnitine, it may exhibit comparable pharmacokinetic properties, including absorption via the gastrointestinal tract, distribution predominantly in muscle tissue, and renal excretion. Nevertheless, definitive ADME profiles require experimental confirmation.
Safety and toxicity profiles for levocarnitine propionate are currently undefined. As an experimental agent, it has not undergone extensive clinical evaluation, and thus potential adverse effects, contraindications, or interactions are not established. This lack of data necessitates caution in handling and investigational use.
There are no notable branded pharmaceutical products or widespread clinical usage contexts associated with levocarnitine propionate at this time. Its current status is limited to experimental research applications.
For formulation scientists and API sourcing professionals, it is important to ensure that levocarnitine propionate is procured from manufacturers adhering to stringent quality standards, such as Good Manufacturing Practice (GMP). Analytical verification of identity, purity, and compliance with regulatory specifications is critical to support investigational use and potential future development.
Pharmacologically, levocarnitine propionate is presumed to act similarly to other carnitine esters by facilitating the transport of long-chain fatty acids across the mitochondrial membrane. This transport is critical for beta-oxidation and subsequent energy production within cells. However, detailed pharmacodynamic data and explicit mechanism of action for this specific propionate ester remain to be fully characterized in clinical or preclinical settings.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for levocarnitine propionate have not been reported in the available literature. Given its structural relationship to levocarnitine, it may exhibit comparable pharmacokinetic properties, including absorption via the gastrointestinal tract, distribution predominantly in muscle tissue, and renal excretion. Nevertheless, definitive ADME profiles require experimental confirmation.
Safety and toxicity profiles for levocarnitine propionate are currently undefined. As an experimental agent, it has not undergone extensive clinical evaluation, and thus potential adverse effects, contraindications, or interactions are not established. This lack of data necessitates caution in handling and investigational use.
There are no notable branded pharmaceutical products or widespread clinical usage contexts associated with levocarnitine propionate at this time. Its current status is limited to experimental research applications.
For formulation scientists and API sourcing professionals, it is important to ensure that levocarnitine propionate is procured from manufacturers adhering to stringent quality standards, such as Good Manufacturing Practice (GMP). Analytical verification of identity, purity, and compliance with regulatory specifications is critical to support investigational use and potential future development.
Identification & chemistry
| Generic name | Levocarnitine propionate |
|---|---|
| Molecule type | Small molecule |
| CAS | 20064-19-1 |
| UNII | 0HU2UI27HF |
| DrugBank ID | DB15980 |
Formulation & handling
- Levocarnitine propionate is formulated for parenteral administration, requiring sterile powder for solution preparation.
- Its low logP and moderate aqueous solubility indicate potential for aqueous formulation but may need solubility optimization.
- As a small molecule, it does not possess peptide-related stability concerns but requires handling under controlled conditions to maintain sterility.
Regulatory status
Levocarnitine propionate API manufacturers & distributors
Compare qualified Levocarnitine propionate API suppliers worldwide. We currently have 1 companies offering Levocarnitine propionate API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Sinoway industrial Co.,Lt... | Distributor | China | China | CEP, CoA, GMP, ISO9001 | 757 products |
When sending a request, specify which Levocarnitine propionate API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Levocarnitine propionate API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
